%0 Journal Article
%T Coronary Stenting in High Bleeding Risk Patients With Small Coronary Arteries Followed by One-Month Dual Antiplatelet Therapy: Onyx ONE Clear.
%A Moreno R
%A Kandzari DE
%A Kirtane AJ
%A Windecker S
%A Latib A
%A Kedhi E
%A Mehran R
%A Price MJ
%A Simon DI
%A Worthley SG
%A Spriggs D
%A Tolleson T
%A Nazif T
%A Golwala H
%A Kander NH
%A Liew HB
%A Sardella G
%A Tamburino C
%A Lung TH
%A Mahoney C
%A Stone GW
%J J Soc Cardiovasc Angiogr Interv
%V 1
%N 6
%D 2022 Nov-Dec
%M 39132364
暂无%R 10.1016/j.jscai.2022.100432
%X <B>UNASSIGNED: </B>Small reference vessel diameters (RVDs) are a predictor of ischemic events after coronary stenting. Among patients at high bleeding risk (HBR) precluding long-term dual antiplatelet therapy (DAPT), those with small vessel disease (SVD) constitute an especially high-risk subgroup. Here, we evaluated the results of a durable-polymer, coronary zotarolimus-eluting stent (ZES) for the treatment of patients with SVD at HBR with 1-month DAPT.<BR><B>UNASSIGNED: </B>In the prospective, multicenter Onyx ONE (One-Month DAPT) Clear study, 1506 patients at HBR treated with a ZES that discontinued DAPT at 30 days were included. The clinical outcomes of patients undergoing treatment of lesions with an RVD of ≤2.5 mm (SVD group, as determined by the angiographic core laboratory) were compared with patients without SVD. The primary end point was the composite of cardiac death or myocardial infarction between 1 and 12 months.<BR><B>UNASSIGNED: </B>Small vessel diameter treatment was performed in 489 (32.5%) patients. Patients with SVD were more likely to be women, have undergone a previous percutaneous intervention, and have multivessel coronary artery disease than patients without SVD. There were no significant differences in lesion, device, or procedural success between the groups. The Kaplan-Meier rate estimate of the primary end point was 8.5% and 6.8% in patients with SVD and those without SVD, respectively (P = .425). No significant differences were found in any secondary end point. The Kaplan-Meier rate of stent thrombosis was 0.6% and 0.8% in patients with SVD and those without SVD, respectively (P = .50).<BR><B>UNASSIGNED: </B>Among patients at HBR treated with a ZES and 1-month DAPT, those with SVD had favorable 12-month ischemic and bleeding outcomes, which were comparable with those of patients with larger caliber vessels.